0001209191-23-057972.txt : 20231208
0001209191-23-057972.hdr.sgml : 20231208
20231208172236
ACCESSION NUMBER: 0001209191-23-057972
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231206
FILED AS OF DATE: 20231208
DATE AS OF CHANGE: 20231208
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gibson Christopher
CENTRAL INDEX KEY: 0001856369
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 231476379
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-12-06
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856369
Gibson Christopher
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
1
1
0
0
Chief Executive Officer
0
Class A Common Stock
2023-12-06
4
C
0
10000
0.00
A
829907
D
Class A Common Stock
2023-12-06
4
G
0
10000
0.00
D
819907
D
Class A Common Stock
2023-12-06
4
M
0
31250
2.48
A
851157
D
Class A Common Stock
2023-12-06
4
S
0
59829
7.4946
D
791328
D
Stock Option (Right to Buy)
8.55
2033-02-01
Class A Common Stock
0
813600
D
Stock Option (Right to Buy)
11.40
2022-02-04
2032-02-04
Class A Common Stock
0
5436
D
Stock Option (Right to Buy)
11.40
2032-02-04
Class A Common Stock
0
407676
D
Stock Option (Right to Buy)
2.48
2023-12-06
4
M
0
31250
0.00
D
2030-12-30
Class A Common Stock
31250
406250
D
Class B Common Stock
0.00
2023-12-06
4
C
0
10000
0.00
D
Class A Common Stock
10000
6491496
D
Class B Common Stock
0.00
Class A Common Stock
4000
519000
I
by LAHWRAN-3 LLC
Class B Common Stock
0.00
Class A Common Stock
20000
428000
I
by LAHWRAN-4 LLC
Class B Common Stock
0.00
Class A Common Stock
1000
119875
I
by Gibson Family Trust
Represents the automatic conversion of Class B Common Stock into Class A Common Stock in connection with a bona-fide gift of shares by the Reporting Person
This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 22, 2022.
This transaction was executed in multiple trades at prices ranging from $7.21 to $8.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
/s/ Jonathan Golightly, attorney-in-fact
2023-12-08